Florida Medicaid
Executive Summary
Florida Medicaid's preferred drug list will include Pfizer's Zoloft, Forest's Lexapro and GlaxoSmithKline's Paxil CR, Wellbutrin XL and Lamictal after the manufacturers renegotiated prices for the mental health products. The drugs were not initially recommended for inclusion by the Florida pharmacy & therapeutics committee under revisions to the Medicaid PDL (1"The Pink Sheet" July 11, 2005, p. 11). Wyeth's Effexor XR and Lilly's antidepressants (Cymbalta, Prozac Weekly, Sarafem) and antipsychotics (Zyprexa and Symbyax) are among the products that will require prior authorization...
You may also be interested in...
Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List
Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.